New wonder drug saves Cystic Fibrosis sufferers from COVID-19 infection
It threatened to be a calamitous year for those affected by Britain’s most widespread inherited illness, cystic fibrosis.
The disease which attacks patients’ lungs, leaving them dangerously susceptible to airborne infections.
The appearance of Covid-19 – which can cause deadly lung disease and pneumonia in healthy individuals – triggered serious alarm among doctors, carers, and patients.
“We were really worried that this previously unknown virus could be particularly bad news for people with cystic fibrosis,” said Keith Brownlee, a director at the Cystic Fibrosis Trust. “We thought this could be very dangerous.”
Yet 2020 has not turned out to be the disastrous year for cystic fibrosis patients that had been anticipated.
They have proved to be largely resilient to the threat of Covid-19 infections while the release of a new class of treatments for the condition has made remarkable improvements to the lives of many of the 10,600 people in Britain who have the disease.
Given the grim prognosis for cystic fibrosis patients that was being forecast at the beginning of the Covid-19 pandemic, this has certainly been a remarkable transformation in fortunes for many patients.
Share on your Social Networks